After finishing at $0.97 in the prior trading day, Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.70, down -27.55%. In other words, the price has decreased by -$0.2673 from its previous closing price. On the day, 6560000 shares were traded. SGMO stock price reached its highest trading level at $0.9250 during the session, while it also had its lowest trading level at $0.7000.
Ratios:
Our goal is to gain a better understanding of SGMO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on November 03, 2023, Downgraded its rating to Sector Perform and sets its target price to $2 from $6 previously.
On April 28, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $5 to $1.50.
Wedbush Upgraded its Neutral to Outperform on February 27, 2023, while the target price for the stock was maintained at $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 26 ’23 when BIOGEN INC. sold 6,000,000 shares for $0.50 per share. The transaction valued at 3,000,000 led to the insider holds 17,652,466 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 125.77M and an Enterprise Value of 82.87M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.71 while its Price-to-Book (P/B) ratio in mrq is 1.51. Its current Enterprise Value per Revenue stands at 0.47 whereas that against EBITDA is -0.86.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $1.94, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is 0.7604, while the 200-Day Moving Average is calculated to be 0.7935.
Shares Statistics:
The stock has traded on average 2.28M shares per day over the past 3-months and 2.52M shares per day over the last 10 days, according to various share statistics. A total of 178.13M shares are outstanding, with a floating share count of 158.21M. Insiders hold about 11.57% of the company’s shares, while institutions hold 48.96% stake in the company. Shares short for SGMO as of Feb 29, 2024 were 10.06M with a Short Ratio of 4.41, compared to 9.98M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.67% and a Short% of Float of 6.61%.
Earnings Estimates
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.27, while EPS last year was $0.12. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.08 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.23 and -$0.77 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.25, with 8 analysts recommending between $0.28 and -$0.64.
Revenue Estimates
6 analysts predict $6.65M in revenue for the current quarter. It ranges from a high estimate of $11.3M to a low estimate of $2M. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $157.96M, an estimated decrease of -95.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $8.24M, a decrease of -44.40% over than the figure of -$95.80% in the same quarter last year. There is a high estimate of $17.8M for the next quarter, whereas the lowest estimate is $2M.
A total of 7 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $95M, while the lowest revenue estimate was $13.8M, resulting in an average revenue estimate of $45.88M. In the same quarter a year ago, actual revenue was $176.23M, down -74.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $79.01M in the next fiscal year. The high estimate is $229M and the low estimate is $26.4M. The average revenue growth estimate for next year is up 72.20% from the average revenue estimate for this year.
